These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 17459273)

  • 1. Bone metabolism and new targets for intervention.
    Akduman B; Crawford ED
    Curr Urol Rep; 2007 May; 8(3):233-8. PubMed ID: 17459273
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bone-targeting agents in prostate cancer.
    Suzman DL; Boikos SA; Carducci MA
    Cancer Metastasis Rev; 2014 Sep; 33(2-3):619-28. PubMed ID: 24398856
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interactions between cancer cells and bone microenvironment promote bone metastasis in prostate cancer.
    Zhang X
    Cancer Commun (Lond); 2019 Nov; 39(1):76. PubMed ID: 31753020
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Skeletal-related events in prostate cancer.
    Smith MR
    Clin Adv Hematol Oncol; 2012 Aug; 10(8):535-6. PubMed ID: 23073052
    [No Abstract]   [Full Text] [Related]  

  • 5. Agents targeting prostate cancer bone metastasis.
    Mohammad KS; Fournier PG; Guise TA; Chirgwin JM
    Anticancer Agents Med Chem; 2009 Dec; 9(10):1079-88. PubMed ID: 19719455
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bone microenvironment-targeted manipulations for the treatment of osteoblastic metastasis in castration-resistant prostate cancer.
    Msaouel P; Nandikolla G; Pneumaticos SG; Koutsilieris M
    Expert Opin Investig Drugs; 2013 Nov; 22(11):1385-400. PubMed ID: 24024652
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [The effect of bisphosphonates on bone metastasis of hormone-refractory prostate cancer].
    Tanaka T; Kawashima H; Kuratsukuri K; Sugimura K; Nakatani T
    Hinyokika Kiyo; 2006 Jun; 52(6):491-4. PubMed ID: 16848364
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Role of the Microenvironment in Prostate Cancer-Associated Bone Disease.
    Turner CJ; Edwards CM
    Curr Osteoporos Rep; 2016 Oct; 14(5):170-7. PubMed ID: 27566487
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Markers of bone metabolism in prostate cancer.
    Smith MR
    Cancer Treat Rev; 2006; 32 Suppl 1():23-6. PubMed ID: 16680835
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Abiraterone and increased survival in metastatic prostate cancer.
    Parker C; Sartor O
    N Engl J Med; 2011 Aug; 365(8):767. PubMed ID: 21864180
    [No Abstract]   [Full Text] [Related]  

  • 11. Bone targeted therapies in metastatic castration-resistant prostate cancer.
    Rajpar S; Fizazi K
    Cancer J; 2013; 19(1):66-70. PubMed ID: 23337759
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bone marrow fat: linking adipocyte-induced inflammation with skeletal metastases.
    Hardaway AL; Herroon MK; Rajagurubandara E; Podgorski I
    Cancer Metastasis Rev; 2014 Sep; 33(2-3):527-43. PubMed ID: 24398857
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Current trials using bone-targeting agents in prostate cancer.
    Tu SM; Lin SH
    Cancer J; 2008; 14(1):35-9. PubMed ID: 18303481
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prostate cancer cell survival pathways activated by bone metastasis microenvironment.
    Tenta R; Sotiriou E; Pitulis N; Thyphronitis G; Koutsilieris M
    J Musculoskelet Neuronal Interact; 2005 Jun; 5(2):135-44. PubMed ID: 15951629
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molecular mechanisms and targeted therapy for the metastasis of prostate cancer to the bones (Review).
    Xu Y; Zhang G; Liu Y; Liu Y; Tian A; Che J; Zhang Z
    Int J Oncol; 2024 Nov; 65(5):. PubMed ID: 39301646
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Bone-targeted treatment in prostate cancer].
    Géczi L; Sinkovics I
    Magy Onkol; 2014 Sep; 58(3):199-203. PubMed ID: 25260084
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The use of bisphosphonates in the management of bone metastatic prostate cancer.
    Mercadante S
    Curr Urol Rep; 2002 Jun; 3(3):244-9. PubMed ID: 12084196
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Use of bisphosphonates in the treatment of prostate cancer.
    Olson KB; Pienta KJ
    Oncology (Williston Park); 2000 Sep; 14(9):1361-4; discussion 1364-7. PubMed ID: 11033832
    [No Abstract]   [Full Text] [Related]  

  • 19. Targeting bone metastasis in prostate cancer with endothelin receptor antagonists.
    Carducci MA; Jimeno A
    Clin Cancer Res; 2006 Oct; 12(20 Pt 2):6296s-6300s. PubMed ID: 17062717
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Re: A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma.
    Berruti A; Tucci M; Terrone C; Scarpa RM; Angeli A; Dogliotti L
    J Natl Cancer Inst; 2003 Feb; 95(4):332-3; author reply 333-4. PubMed ID: 12591993
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 12.